SPYRE THERAPEUTICS, INC. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
SPYRE THERAPEUTICS, INC. (SYRE) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $0 as of 2023-12-31, per its 10-K/A filed 2024-11-18.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2024-11-18
- 2023-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2022-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $597.00K.
- 2021-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $798.00K.
- 2020-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $68.00K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2023-12-31 | $0.00 10-K/A · filed 2024-11-18 |
| 2022-12-31 | $597.00K 10-K/A · filed 2024-11-18 |
| 2021-12-31 | $798.00K 10-K · filed 2023-03-02 |
| 2020-12-31 | $68.00K 10-K · filed 2022-03-08 |
| 2019-12-31 | $56.00K 10-K · filed 2021-03-18 |
| 2019-09-30 | $63.00K 10-Q · filed 2019-11-06 |
| 2019-06-30 | $70.00K 10-Q · filed 2019-08-06 |
| 2019-03-31 | $78.00K 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |